

NOVEL ANTIBODIES AND LIGANDS FOR "BONZO"  
CHEMOKINE RECEPTOR

ABSTRACT OF THE DISCLOSURE

The invention relates to an antibody or antigen-binding fragment thereof which  
5 binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR  
and HBMBU14) and blocks the binding of a ligand (e.g., SExCkine (also referred to as  
chemokine alpha-5) to the receptor. The invention also relates to a method of  
identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the  
binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The  
10 invention relates to an antibody or antigen-binding fragment thereof which binds to the  
CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding  
of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules  
which contain a first binding moiety which binds to mammalian Bonzo and a second  
binding moiety which binds to a molecule expressed on the surface of a target cell. The  
15 invention also relates to a method of promoting and/or effectuating the interaction of a  
Bonzo<sup>+</sup> cell and a target cell. The invention further relates to a method of modulating a  
function of Bonzo, and to the use of the antibodies, antigen-binding fragments, targeting  
molecules and agents identified by the method of the invention in research, therapeutic,  
prophylactic and diagnostic methods.

TOC2280"E9004650